This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study of Carboplatin/Gemcitabine Plus Bevacizumab in Advanced Lung Cancer

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified September 2005 by St. John Providence Health System.
Recruitment status was:  Recruiting
Genentech, Inc.
Eli Lilly and Company
Information provided by:
St. John Providence Health System Identifier:
First received: September 6, 2005
Last updated: November 28, 2005
Last verified: September 2005
  • this study is being done to find out if the combination of carboplatin and gemcitabine will be more effective in the the treatment of advanced lung cancer if bevacizumab, an agent that blocks tumor blood vessel formation, is added
  • the study will measure the time to progression of patients treated with the combination; we hope to show that the addition of bevacizumab improves the time to progression (increases the amount of time before the disease begins to worsen)
  • all patients receive all three drugs; there is no placebo

Condition Intervention Phase
Non-Small Cell Lung Cancer Drug: bevacizumab Drug: carboplatin Drug: gemcitabine Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Trial of Carboplatin/Gemcitabine Plus Bevacizumab in Advanced Non-Small Cell Lung Cancer

Resource links provided by NLM:

Further study details as provided by St. John Providence Health System:

Primary Outcome Measures:
  • time to progression

Secondary Outcome Measures:
  • response rate
  • median survival
  • one year survival
  • two year survival
  • toxicity

Estimated Enrollment: 45
Study Start Date: November 2004
Detailed Description:
  • Patients with advanced (stage IV, and Stage IIIB with effusion) non-small cell lung cancer with non-squamous histology, good performance status, and adequate organ function are eligible.
  • Patients with brain metastases, squamous histology, or hemoptysis are excluded.
  • All patients must give informed consent.
  • Schema gemcitabine 1250 mg/M2 IV day 1,8 carboplatin AUC 5 IV day 1 bevacizumab 15 mg/kg IV day 1 repeated every 21 days for 6 cycles

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically or cytologically proven non-small cell lung cancer, newly diagnosed or recurrent after previous surgery and/or radiation therapy
  • Stage IV disease or stage IIIB with a malignant pleural effusion
  • measurable or evaluable disease
  • Performance status 0 or 1 (ECOG)
  • adequate renal, hepatic, and bone marrow function
  • adequate recovery from previous surgery or radiotherapy
  • informed consent

Exclusion Criteria:

  • brain metastases
  • squamous (epidermoid) histology
  • hemoptysis
  • central airway disease
  • Pancoast tumors
  • previous chemotherapy or biologic therapy for lung cancer
  • prior malignancy within the previous 5 years except non-melanoma skin cancer or cervical CIS
  • pregnant or nursing women
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00150657

Contact: Michael J Kraut, MD 248-849-3541
Contact: Jaswinder Grewal, PhD 248-849-5337

United States, Michigan
Providence Cancer Institute Recruiting
Southfield, Michigan, United States, 48075
Contact: Michael J Kraut, MD    248-849-8155   
Contact: Howard Terebelo, DO    248-552-0620      
Principal Investigator: Michael J Kraut, MD         
Sub-Investigator: Howard Terebelo, DO         
Sub-Investigator: Anibal Drelichman, MD         
Sub-Investigator: Robert Bloom, MD         
Sub-Investigator: Lyle Goldman, MD         
Sub-Investigator: Judie Goodman, DO         
Sponsors and Collaborators
St. John Providence Health System
Genentech, Inc.
Eli Lilly and Company
Principal Investigator: Michael J Kraut, MD Providence Cancer Institute
  More Information Identifier: NCT00150657     History of Changes
Other Study ID Numbers: AVF3121s
Study First Received: September 6, 2005
Last Updated: November 28, 2005

Additional relevant MeSH terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors processed this record on August 18, 2017